We aimed to observe the effect of pulse steroid therapy used in the hyperinflammatory phase that occurs during the course of the COVID-19 disease on the inflammatory markers and clinical conditions of the patients.In this study, 30 patients with positive COVID-19 PCR (polymerase chain reaction) test who were treated with pulse steroid (high-dose methylprednisolone) due to the hyperinflammatory phase were evaluated. The clinical conditions and inflammatory markers of the patients were retrospectively analyzed. Patients were evaluated in terms of age, gender, intubation status, clinical improvement, discharge, mortality rate, 24th, 48th, 72nd hours and 7th days after treatment initiation, C-reactive protein (CRP), procalcitonin, ferritin, oxygen saturation values, lymphocyte count.A total of 30 patients; 21 male and 9 female, who received pulse steroid therapy were examined. The median age was calculated as 66 [31-88]. In the study, 15 (50%) patients died, of which 11 were male and 4 were female. When the survived and deceased patients were compared, it was observed that the values of ferritin, CRP procalcitonin measured at 72 hours and 7 days after pulse steroid treatment decreased significantly in the survived patient group. (72nd hour p-values=0.01-0.08- <0.05, respectively) (7th day p-value=0.01-0.07-<0.05, respectively)The significant decrease in inflammatory markers such as ferritin and CRP after pulse steroid therapy and the fact that this decrease is more obvious in the survived patient group suggests that steroids can be used in hyperinflammatory processes.